Truist Securities Initiates Coverage On Axogen with Buy Rating, Announces Price Target of $60
Truist Securities analyst Ravi Misra initiates coverage on Axogen (NASDAQ:AXGN) with a Buy rating and announces Price Target of $60.
Stocks · News reference
Axogen Participates In Series A Funding Round For Trace Biosciences With Additional Investors Expected To Join; Terms Not Disclosed
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading